European Archives - Page 286 of 1425 - European Medical Journal

Nanomedicine in Diabetes Treatment: Novel Drug Delivery Systems

Diabetes is a chronic metabolic disorder characterised by persistently high blood sugar levels (hyperglycaemia) caused by deficiencies…

Target-Like Lesions with Mucositis Due to Co-Infection with Mycoplasma pneumoniae and Varicella-Zoster Virus

Cases involving co-infections with Mycoplasma pneumoniae and varicella-zoster virus (VZV) are exceedingly rare in medical literature…

Oesophageal Actinomycosis Masquerading as Squamous Cell Carcinoma

The Actinomyces family includes 47 different species. Actinomycosis infections are characterised by abscess formation, granulation…

Gold coins on blue background

UK to raise branded drug repayment rate to over 30%

The UK will hike statutory payment rates for branded drugs to over 30% in 2025, far surpassing other European markets and raising concerns.

Man contemplates different paths to go down

Education or promotion: What wins with HCPs?

When every second of a healthcare professional’s time counts, what content truly earns their attention – disease awareness or product promotion?

EULAR 2025: MRI Detects Early Spinal Changes in axSpA

Presented at EULAR 2025, new 2-year data from the SPACE cohort show that spinal fat lesions on MRI progress in early axial spondyloarthritis, unlike in non-axSpA chronic back pain.

Secondary Bacterial Peritonitis Following a Renal Abscess

Bacterial peritonitis can either arise spontaneously or occur secondary to abscesses or perforations in the abdominal cavity. Both…

Newborn Gut Bacteria Linked to Respiratory Risk in Early Childhood

Early differences in newborn gut microbiota composition may influence risk of hospitalisation for viral lower respiratory tract infections in early childhood.

Diabetes Weight Loss Drugs May Double Risk of Macular Degeneration

GLP-1 RAs may significantly increase the risk of neovascular age-related macular degeneration in older adults with diabetes.

Breakthrough mRNA Delivery Technology Could Reverse HIV Latency

A groundbreaking approach using mRNA-lipid nanoparticle technology has shown the ability to force HIV out of its latent state, offering hope for future curative therapies.